Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction

Korean Journal of Internal Medicine

Volumn 26, Issue 3, 2011, Pages 294-303

  Kim, Min Chul ^a   Ahn, Youngkeun ^a   Jang, Su Young ^a   Cho, Kyung Hoon ^a   Hwang, Seung Hwan ^a   Lee, Min Goo ^a   Ko, Jum Suk ^a   Park, Keun Ho ^a   Sim, Doo Sun ^a   Yoon, Nam Sik ^a   Yoon, Hyun Ju ^a   Kim, Kye Hun ^a   Hong, Young Joon ^a   Park, Hyung Wook ^a   Kim, Ju Han ^a   Jeong, Myung Ho ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Hydroxymethylglutaryl coa reductase inhibitors; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; HEPARIN; LIPID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; FATALITY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYDROPHILICITY; INFECTION; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPOPHILICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RETREATMENT; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KOREA; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054862891     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2011.26.3.294     Document Type: Article

References (26)

1. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316.
2. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
3. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445.
4. Lenderink T, Boersma E, Gitt AK, et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 2006;27:1799-1804.
5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
6. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
7. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-283.
8. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-1304.
9. Zile MR. Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation 2005;112:300-303.
10. Yoon HE, Song JC, Hyoung BJ, et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J Intern Med 2009;24:233-237.
11. Park JS, Kim YJ, Choi JY, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med 2010;25:27-35.
12. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003;26(4 Suppl 3):III32-III38.
13. Sakamoto T, Kojima S, Ogawa H, et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ J 2007;71:1348-1353.
14. Kai T, Arima S, Taniyama Y, Nakabou M, Kanamasa K. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. Clin Exp Hypertens 2008;30:530-540.
15. Fujita M, Yamazaki T, Hayashi D, et al. Pleiotropic effects of statins on cardiovascular events in the Japanese Coronary Artery Disease study. Int J Cardiol 2008;129:294-296.
16. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-2241.
17. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157.
18. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513.
19. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538.
20. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
21. Glasser SP, Wadley V, Judd S, et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol 2010;33:280-288.
22. Kato S, Smalley S, Sadarangani A, et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med 2010;14:1180-1193.
23. Salman H, Bergman M, Djaldetti M, Bessler H. Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed Pharmacother 2008;62:41-45.
24. Li YH, Wu HL, Yang YH, Tsai HS, Chao TH. Effect of early versus late in-hospital initiation of statin therapy on the clinical outcomes of patients with acute coronary syndrome. Int Heart J 2007;48:677-688.
25. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
26. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678.